ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancerS. Lindsey Davis(University of Colorado Cancer Center), Todd M. Pitts(University of Colorado Denver)BMC CancerOctober 29, 202210.1186/s12885-022-10084-7Cited by 27SaveCiteExport RISWatch citationsRelated PapersDual Pharmacological Targeting of the MAP Kinase and PI3K/mTOR Pathway in Preclinical Models of Colorectal Cancer|PLoS ONE|2014|52Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis|Breast Cancer Research|2024|26